Capital Insight Partners LLC Raises Stake in UnitedHealth Group Incorporated (NYSE:UNH)

Capital Insight Partners LLC increased its stake in shares of UnitedHealth Group Incorporated (NYSE:UNH - Free Report) by 5.5% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 9,247 shares of the healthcare conglomerate's stock after buying an additional 480 shares during the period. Capital Insight Partners LLC's holdings in UnitedHealth Group were worth $4,678,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Kathleen S. Wright Associates Inc. purchased a new position in UnitedHealth Group during the 3rd quarter valued at about $27,000. AlphaMark Advisors LLC acquired a new position in shares of UnitedHealth Group during the 4th quarter worth approximately $30,000. West Financial Advisors LLC purchased a new position in UnitedHealth Group during the third quarter worth $32,000. Quarry LP lifted its position in shares of UnitedHealth Group by 132.1% in the second quarter. Quarry LP now owns 65 shares of the healthcare conglomerate's stock valued at $33,000 after acquiring an additional 37 shares in the last quarter. Finally, RPg Family Wealth Advisory LLC acquired a new position in UnitedHealth Group in the 3rd quarter valued at about $37,000. 87.86% of the stock is owned by hedge funds and other institutional investors.

UnitedHealth Group Stock Down 0.6 %

NYSE UNH opened at $542.30 on Friday. The stock has a market cap of $499.07 billion, a PE ratio of 34.99, a P/E/G ratio of 1.46 and a beta of 0.62. The business has a 50 day moving average price of $536.17 and a two-hundred day moving average price of $565.14. UnitedHealth Group Incorporated has a fifty-two week low of $436.38 and a fifty-two week high of $630.73. The company has a quick ratio of 0.91, a current ratio of 0.83 and a debt-to-equity ratio of 0.74.

UnitedHealth Group (NYSE:UNH - Get Free Report) last issued its quarterly earnings data on Thursday, January 16th. The healthcare conglomerate reported $6.81 EPS for the quarter, topping analysts' consensus estimates of $6.74 by $0.07. UnitedHealth Group had a net margin of 3.60% and a return on equity of 26.69%. The firm had revenue of $100.81 billion for the quarter, compared to analyst estimates of $101.60 billion. During the same quarter in the previous year, the business posted $5.83 EPS. The firm's revenue was up 6.8% compared to the same quarter last year. As a group, sell-side analysts predict that UnitedHealth Group Incorporated will post 29.64 EPS for the current fiscal year.

UnitedHealth Group Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, December 17th. Investors of record on Monday, December 9th were paid a $2.10 dividend. The ex-dividend date of this dividend was Monday, December 9th. This represents a $8.40 dividend on an annualized basis and a dividend yield of 1.55%. UnitedHealth Group's dividend payout ratio (DPR) is presently 54.19%.

Insiders Place Their Bets

In other news, Director Timothy Patrick Flynn purchased 1,000 shares of the company's stock in a transaction that occurred on Friday, January 17th. The shares were acquired at an average cost of $511.57 per share, with a total value of $511,570.00. Following the transaction, the director now owns 4,500 shares in the company, valued at approximately $2,302,065. The trade was a 28.57 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.33% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the stock. Truist Financial lowered their price target on shares of UnitedHealth Group from $625.00 to $610.00 and set a "buy" rating for the company in a report on Monday, January 6th. Deutsche Bank Aktiengesellschaft increased their price target on UnitedHealth Group from $595.00 to $625.00 and gave the stock a "buy" rating in a research note on Tuesday, December 3rd. Bank of America dropped their target price on UnitedHealth Group from $675.00 to $650.00 and set a "buy" rating for the company in a research note on Wednesday, October 16th. KeyCorp restated an "overweight" rating and issued a $650.00 price target on shares of UnitedHealth Group in a report on Friday, January 17th. Finally, UBS Group lowered their target price on shares of UnitedHealth Group from $680.00 to $650.00 and set a "buy" rating for the company in a report on Wednesday, October 16th. One analyst has rated the stock with a hold rating, twenty have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average target price of $629.32.

UnitedHealth Group Company Profile

UnitedHealth Group Incorporated operates as a diversified health care company in the United States. The company operates through four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The UnitedHealthcare segment offers consumer-oriented health benefit plans and services for national employers, public sector employers, mid-sized employers, small businesses, and individuals; health care coverage, and health and well-being services to individuals age 50 and older addressing their needs; Medicaid plans, children's health insurance and health care programs; and health and dental benefits, and hospital and clinical services, as well as health care benefits products and services to state programs caring for the economically disadvantaged, medically underserved, and those without the benefit of employer-funded health care coverage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.